Mavacamten

8 · 20 / page

Ask MedXY AI

Latest news

Tag

AIHypertrophic CardiomyopathyMavacamten

AI-Enabled ECG as a New Surveillance Tool for Left Ventricular Dysfunction in Hypertrophic Cardiomyopathy on Mavacamten

By MedXY|Aug 12, 2026

This study explores the potential of an AI-powered ECG tool to monitor left ventricular systolic dysfunction in hypertrophic cardiomyopathy patients treated with mavacamten, offering a less burdensome alternative to frequent echocardiograms

Targeting Skeletal Muscle Myosin ATPase May Reduce Resting Energy Waste in Heart Failure With Reduced Ejection Fraction

CardiologyHFrEF

Mavacamten

Latest news

AI-Enabled ECG as a New Surveillance Tool for Left Ventricular Dysfunction in Hypertrophic Cardiomyopathy on Mavacamten

Targeting Skeletal Muscle Myosin ATPase May Reduce Resting Energy Waste in Heart Failure With Reduced Ejection Fraction

Mavacamten Achieves Surgical-Grade Hemodynamic Correction in Obstructive Hypertrophic Cardiomyopathy by Reversing the Anrep Response

Mavacamten Redefines Long-Term Outcomes in Obstructive Hypertrophic Cardiomyopathy: 128-Week Results From the VALOR-HCM Trial

Echocardiographic Remodeling and Atrial Dynamics with Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Insights from the ODYSSEY-HCM Trial

Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial

Evaluating Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Insights from the ODYSSEY-HCM Trial

Long-Term Benefits and Safety of Mavacamten in Obstructive Hypertrophic Cardiomyopathy: Insights from the VALOR-HCM 128-Week Study